As it has been recently demonstrated that BzATP treatment induce the activation of PI3K/Akt and ERK1/2 signaling pathways in prostate cancer cells [42], we exposed cells with ERK1/2 inhibitor, PD98059 (10 μM), added to the culture medium 30 min prior to BzATP treatment until the end of experiment. The gene discussed is MAPK3; the disease is prostate carcinoma.